Yong Fang,
Yi Hu,
Peng Wu,
Beibei Wang,
Yuan Tian,
Xi Xia,
Qinghua Zhang, Tong Chen,
Xuefeng Jiang,
Quanfu Ma,
Gang Xu,
Shixuan Wang,
Jianfeng Zhou,
Ding Ma,
Li Meng
[show abstract]
[hide abstract]
ABSTRACT: Histone deacetylase inhibitors and proteasome inhibitor are all emerging as new classes of anticancer agents. We chose TSA and PS-341 to identify whether they have a synergistic efficacy on human ovarian cancer cells. After incubated with 500 nM TSA or/and 40 nM PS-341, we found that combined groups resulted in a striking increase of apoptosis and G2/M blocking rates, no matter in A2780, cisplatin-sensitive ovarian cancer cell line OV2008 or its resistant variant C13*. This demonstrated that TSA interacted synergistically with PS-341, which raised the possibility that combined the two drugs may represent a novel strategy in ovarian cancer.
Cancer Investigation 02/2011; 29(4):247-52. · 1.85 Impact Factor
